Stage IV Lymphoepithelioma of the Nasopharynx Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0029528 (Stage IV Lymphoepithelioma of the Nasopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00408694Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal CancerTreatment
NCT00492089Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerSupportive Care